학술논문
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial
Document Type
Article
Author
Source
In Journal of Thoracic Oncology December 2023 18(12):1743-1755
Subject
Language
ISSN
1556-0864